Global NGS Informatics and Clinical Genomics Market

Global NGS Informatics and Clinical Genomics Market: Focus on Product Types (LIMS, Data Analysis and Interpretation Tools, and Storage and Computing Solutions), End Users, and Regional Analysis for 21 Countries: Analysis and Forecast (2018-2028)

The global NGS informatics and clinical genomics market encompasses major regions such as North America, Europe, Asia-Pacific, Middle East and Africa, and Rest-of-the-World (RoW). North America is the leading region in the NGS informatics and clinical genomics market accounting for approximately 45.45% and has an estimated value of $380.0 million (as of 2017).

SKU: BH076A
Published Year: 2018
PLEASE SELECT A LICENSE TYPE
 
 
 

The global NGS informatics and clinical genomics market is composed of tools, software solutions and services catering for the data analysis needs of the NGS market. Despite the technological advancement in the field of next generation sequencing, analysing huge datasets coming out of sequencers remains a major challenge in the industry that prevents the NGS technology to be used as a routine technique.

There are three significant forms of NGS data analysis: primary, secondary, and tertiary analysis. The software platforms or tools catering for NGS data analysis either perform primary, secondary, and tertiary data analysis. However, there are software packages available which provide end to end (primary to tertiary) data analysis solutions. Some of the major analysis performed by NGS software tools include image acquisition, quality control, base calling, alignment to a reference genome, variant calling, and biological interpretation.

In the primary analysis stage, the raw data is converted to sequence data wherein the base pairs in a genome are typically identified by laser excitation or fluorescence detection. A primary data analysis tool is a part of sequencing instruments and is typically installed on the local hardware systems supporting sequencing instruments. The resultant of this data analysis stage is usually a FASTQ file (string of characters: A, C, T, G, and N). In the secondary data analysis stage, reads generated (short genomic sequences) are aligned against a reference genome. Once the file is aligned, a BAM file is generated which is subject to further refinement steps such as flagging or filtering of duplicate reads, recalibration of quality scores (in the first stage), and variant calling with the help of various statistical modelling techniques. The variant calling step determines the point of difference between the sample and the reference genome. The last and the most complex and time-consuming phase of NGS data analysis is tertiary analysis. This stage aims at identifying which variants in a sample are benign, pathogenic, or VUS (variant of unknown clinical significance). The complexity of the stage can be understood from the fact that one human exome may have approximately 3.2 million variants and interpretation of each of the variants become a daunting task for the industry.

The market report is well-designed to provide an all-inclusive field of vision about the global NGS informatics and clinical genomics market in terms of various factors, such as recent trends, technological advancements, competitive landscape, and regulatory environment of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the global NGS informatics and clinical genomics market. The market has been segmented into “Technology” ‘Products’, ‘End Users’, and ‘Region’. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global NGS informatics and clinical genomics market with the help of the key factors driving the market, challenges, and threats that can possibly inhibit the overall growth of the market and the current investment opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global NGS informatics and clinical genomics market and assesses the factors governing the same.

The answers to the following key questions can be derived from this report:

•    What are the major market drivers, challenges, and opportunities in the global NGS informatics and clinical genomics market?
•    What was the market value of the leading segments and sub-segments of the global NGS informatics and clinical genomics market in 2017?
•    How will each segment of the global NGS informatics and clinical genomics market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
•    What are the influencing factors that may affect the market share of the leading players?
•    How will the industry evolve during the forecast period 2018-2028?
•    What are the key developments and strategies that are implemented by the key players to sustain in this market?
•    What are the potential end users of the global NGS informatics and clinical genomics market? How NGS informatics and clinical genomics software platforms will boost the performance of different end users?
•    Who are the key players in the global NGS informatics and clinical genomics market, and what are their contributions?
•    What is the scope of expansion by the key players of the global NGS informatics and clinical genomics market in Asia-Pacific, Europe, and Middle East?

Furthermore, to bring the competitive landscape of NGS informatics and clinical genomics market into perspective, there is a wide range of providers competing under different sub-segments of the market. For example, there are primary and secondary data analysis tools providers such as Illumina (primary and secondary), ThermoFisher (primary and secondary), Qiagen (primary and secondary), Edico Genome (secondary only), and Genalice among others.  In addition, there is a plethora of companies providing storage and computing solutions (such as Google Cloud, Amazon Web Services and Microsoft, among others), LIMS solutions (such as Thermo Scientific Clinical LIMS, Core LIMS, and STARLIMS, among others) and data interpretation and reporting tools (such as Qiagen (QCI Interpret), Genoox, and Annai Systems, among others)

   Executive Summary
   1   Market Overview
        1.1   Introduction to NGS Informatics and Clinical Genomics
        1.2   Cost of NGS Data Analysis
        1.3   Role of NGS Informatics in Precision Medicine?
        1.4   Approach to Precision Medicine
        1.5   Evolution of Precision Medicine Technology
        1.6   The Wave of Data Types: NGS Data Remains the Leading Data Type for Precision Medicine
                1.6.1   Overview
                1.6.2   Genomic Data
                1.6.3   Lifestyle and Environment
                1.6.4   Health Information
                1.6.5   Social Media
        1.7   Healthcare Information Technology: A Boon for NGS informatics Market
        1.8   The Correlation Between NGS Informatics and Clinical Genomics
        1.9   Technologies with the Potential to Incorporate NGS in a Clinical Setting
                1.9.1   Electronic Health Records (EHR)
                1.9.2   Health Information Exchange
                1.9.3   Clinical Decision Support Systems (CDSS)
                1.9.4   Population Health Management (PHM)
                1.9.5   Blockchain
                1.9.6   Artifical Intelligence/Machine Learning
                1.9.7   Big Data Analytics
 
   2   Market Dynamics
        2.1   Impact Analysis
        2.2   Market Drivers
                2.2.1   Low cost Sequencing Platforms
                2.2.2   Growth in Clinical Application
                2.2.3   Rise in Genomic Data
                2.2.4   Increasing Number of Population Genomics Initiatives
                2.2.5   Advancements in Big Data Technology
                2.2.6   Reducing Cost of Cloud Storage
        2.3   Market Restraints
                2.3.1   Lack of Integration and Interoperability among Existing Information Systems
                2.3.2   Patient Access to Data
                2.3.3   Data Security and Privacy
                2.3.4   Fragmented Research Environment
        2.4   Market Opportunities
                2.4.1   Cross Industry Collaborations between Health Systems, Academia and Health IT Industry
                2.4.2   Investment in Blockchain Technology and Information Security
                2.4.3   Clinical Application Focussed NGS Informatics Products
                2.4.4   Integration of Clinical and Non-Clinical NGS data
                2.4.5   Automation of Sequencing and Interpretation
 
   3   Competitive Insights
        3.1   Key Strategies and Developments
                3.1.1   Partnerships, Joint Ventures, and Collaborations
                3.1.2   Product Development and Launch
                3.1.3   Business Funding and Contracts
                3.1.4   Mergers and Acquisitions
                3.1.5   Approvals and Certifications
                3.1.6   Others
        3.2   Competitive Scenario: Intense Competition within a Converging Market
 
   4   Industry Attractiveness and Insights
        4.1   Porter’s Five Forces Analysis
        4.2   Bargaining Power of Suppliers
        4.3   Bargaining Power of Buyer
        4.4   Threat of New Entrants
                4.4.1   Threat of Substitute Products
                4.4.2   Intensity of Competitive Rivalry
 
   5   Key Industry Insights
        5.1   Introduction
        5.2   Regulatory Bodies
 
   6   Global NGS Informatics and Clinical Genomics Market: Analysis and Forecast
        6.1   Assumptions & Limitations for Market Size Calculations
 
   7   Global NGS Informatics and Clinical Genomics Market (by Technology)
        7.1   Overview
                7.1.1   Blockchain Genomics Platforms
                7.1.2   Data Aggregation Software
                7.1.3   AI/Machine Learning and Cloud Computing based Genomic Platforms
                7.1.4   Clinical Decision Support based Genomic Platforms
                7.1.5   Artificial Intelligence (AI) based Drug Discovery Platforms
 
   8   Global NGS Informatics and Clinical Genomics Market (by Product Type)
        8.1   Laboratory Information Management Systems (LIMS)
        8.2   NGS Informatics Services (Includes both Sequencing and Consulting Services)
        8.3   Commercial Primary and Secondary Data Analysis Tools
                8.3.1   Primary Data Analysis
                8.3.2   Secondary Data Analysis
        8.4   Storage, Infrastructure, and Computing
        8.5   Interpretation (Tertiary Analysis) Tools
 
   9   Global NGS Informatics and Clinical Genomics Market (by End User)
        9.1   Academics and Research Institutes
        9.2   Biopharmaceutical Industry
        9.3   Diagnostic Industry
        9.4   Government Agencies
        9.5   Hospitals and Clinics
 
  10  Global NGS Informatics and Clinical Genomics Market (by Region)
        10.1   Overview
        10.2   North America
                  10.2.1   The U.S.
                  10.2.2   Canada
        10.3   Europe
                  10.3.1   Germany
                  10.3.2   The U.K.
                  10.3.3   Italy
                  10.3.4   France
                  10.3.5   Spain
                  10.3.6   Rest-of-Europe
                               10.3.6.1   Switzerland
        10.4   Asia-Pacific
                  10.4.1   India
                  10.4.2   China
                  10.4.3   Japan
                  10.4.4   South Korea
                  10.4.5   Australia
                  10.4.6   Singapore
                  10.4.7   Rest-of-Asia-Pacific
        10.5   Rest-of-the-World
                  10.5.1   Brazil
                  10.5.2   Mexico
                  10.5.3   Russia
                  10.5.4   Israel
                  10.5.5   Other countries in RoW
                               10.5.5.1   Saudi Arabia
                               10.5.5.2   United Arab Emirates
                               10.5.5.3   South Africa
 
   11   Company Profiles
          11.1   Overview
          11.2   2bPrecise, LLC
                    11.2.1   Company Overview
                    11.2.2   Company Overview
                    11.2.3   Overall Product Portfolio
                    11.2.4   Product Offerings for Precision Medicine
                    11.2.5   Financials
                                 11.2.5.1   Financial Summary
                    11.2.6   Global Presence
                    11.2.7   Recent Developments
                    11.2.8   SWOT Analysis
          11.3   Cota, Inc.
                    11.3.1   Company Overview
                    11.3.2   Product Portfolio
                    11.3.3   Corporate Summary
                    11.3.4   Recent Developments
                    11.3.5   SWOT Analysis
          11.4   CureMatch, Inc.
                    11.4.1   Company Overview
                    11.4.2   Product Portfolio
                    11.4.3   Corporate Summary
                    11.4.4   Global Presence
                    11.4.5   Recent Developments
                    11.4.6   SWOT Analysis
          11.5   DrChrono Inc.
                   11.5.1   Company Overview
                   11.5.2   Overall Product Portfolio
                   11.5.3   Product Portfolio for Healthcare IT Solutions for Precision Medicine
                   11.5.4   Corporate Summary
                   11.5.5   Global Presence
                   11.5.6   Recent Developments
                   11.5.7   SWOT Analysis
         11.6   Epic Systems Corporation
                   11.6.1   Company Overview
                   11.6.2   Overall Product Portfolio
                   11.6.3   Product Offerings for Precision Medicine
                   11.6.4   Corporate Summary
                   11.6.5   SWOT Analysis
         11.7   Flatiron Health, Inc. (Subsidiary of Roche Group Company)
                   11.7.1   Company Overview
         11.8   F. Hoffmann-La Roche AG
                   11.8.1   Company Overview
                   11.8.2   Overall Product Portfolio
                   11.8.3   Product Offering
                   11.8.4   Financials
                                11.8.4.1   Financial Summary
                   11.8.5   Global Presence
                   11.8.6   Recent Developments
                   11.8.7   SWOT Analysis
         11.9   GenomOncology, LLC
                   11.9.1   Company Overview
                   11.9.2   Product Portfolio
                   11.9.3   Corporate Summary
                   11.9.4   Global Presence
                   11.9.5   Recent Developments
                   11.9.6   SWOT Analysis
         11.10  Interpreta, Inc.
                    11.10.1   Company Overview
                    11.10.2   Product Portfolio
                    11.10.3   Corporate Summary
                    11.10.4   Global Presence
                    11.10.5   Recent Developments
                    11.10.6   SWOT Analysis
         11.11  Illumina, Inc.
                   11.11.1   Company Overview
                   11.11.2   Overall Product Portfolio
                   11.11.3   Product Offering
                   11.11.4   Financials
                                 11.11.4.1   Financial Summary
                   11.11.5   Global Presence
                   11.11.6   Recent Developments
                   11.11.7   SWOT Analysis
         11.12  IBM Corporation
                    11.12.1   Company Overview
                    11.12.2   Overall Product Portfolio
                    11.12.3   Precision Medicine Product Portfolio
                    11.12.4   Financials
                                  11.12.4.1   Financial Summary
                    11.12.5   Global Presence
                    11.12.6   Recent Developments
                    11.12.7   SWOT Analysis
         11.13  Koninklijke Philips N.V.
                    11.13.1   Company Overview
                    11.13.2   Overall Product Portfolio
                    11.13.3   Product Offerings for Precision Medicine
                    11.13.4   Financials
                                   11.13.4.1   Financial Summary
                    11.13.5   Global Presence
                    11.13.6   Recent Developments
                    11.13.7   SWOT Analysis
          11.14  LunaDNA Inc.
                    11.14.1   Company Overview
                    11.14.2   Product Portfolio
                    11.14.3   Corporate Summary
                    11.14.4   Global Presence
                    11.14.5   Recent Developments
                    11.14.6   SWOT Analysis
         11.15   Navican Genomics, Inc.
                     11.15.1   Company Overview
                     11.15.2   Product Portfolio
                     11.15.3   Corporate Summary
                     11.15.4   Global Presence
                     11.15.5   Recent Developments
                     11.15.6   SWOT Analysis
          11.16  N-of-One, Inc.
                     11.16.1   Company Overview
                     11.16.2   Product Portfolio
                     11.16.3   Corporate Summary
                     11.16.4   Global Presence
                     11.16.5   Recent Developments
                     11.16.6   SWOT Analysis
          11.17   NantHealth, Inc.
                      11.17.1   Company Overview
                      11.17.2   Overall Product Portfolio
                      11.17.3   Precision Medicine Product Portfolio
                      11.17.4   Financials
                                     11.17.4.1   Financial Summary
                      11.17.5   Global Presence
                      11.17.6   Recent Developments
                      11.17.7   SWOT Analysis
           11.18  Orion Health Group Limited
                      11.18.1   Company Overview
                      11.18.2   Overall Product Portfolio
                      11.18.3   Product Offerings for Precision Medicine
                      11.18.4   Financials
                                     11.18.4.1   Financial Summary
                      11.18.5   Global Presence
                      11.18.6   Recent Developments
                      11.18.7   SWOT Analysis
           11.19  QIAGEN N.V.
                     11.19.1   Company Overview
                     11.19.2   Overall Product Portfolio
                     11.19.3   Product Offering
                     11.19.4   Financials
                                   11.19.4.1   Financial Summary
                     11.19.5   Global Presence
                     11.19.6   Recent Developments
                     11.19.7   SWOT Analysis
          11.20  SOPHiA GENETICS SA
                     11.20.1   Company Overview
                     11.20.2   Product Portfolio
                     11.20.3   Corporate Summary
                     11.20.4   Global Presence
                     11.20.5   Recent Developments
                     11.20.6   SWOT Analysis
          11.21  Syapse, Inc.
                     11.21.1   Company Overview
                     11.21.2   Product Portfolio
                     11.21.3   Corporate Summary
                     11.21.4   Global Presence
                     11.21.5   Recent Developments
                     11.21.6   SWOT Analysis
          11.22  SAP SE
                     11.22.1   Company Overview
                     11.22.2   Overall Product Portfolio
                     11.22.3   Product Offerings for Precision Medicine
                     11.22.4   Financials
                                    11.22.4.1   Financial Summary
                     11.22.5   Global Presence
                     11.22.6   Recent Developments
                     11.22.7   SWOT Analysis
           11.23  Tempus Labs, Inc.
                      11.23.1   Company Overview
                      11.23.2   Product Portfolio
                      11.23.3   Corporate Summary
                      11.23.4   Global Presence
                      11.23.5   Recent Developments
                      11.23.6   SWOT Analysis
            11.24  Verily Life Sciences LLC
                       11.24.1   Company Overview
                       11.24.2   Overall Product Portfolio
                       11.24.3   Product Offerings for Precision Medicine
                       11.24.4   Corporate Summary
                       11.24.5   Global Presence
                       11.24.6   Recent Developments
                       11.24.7   SWOT Analysis
             11.25  Snapshot of Other Key Industry Players
                        11.25.1   Beijing Genomic Institute (BGI)
                        11.25.2   Amazon Web Services, Inc.
                        11.25.3   DNAnexus, Inc.
                        11.25.4   DNASTAR
                        11.25.5   Eagle Genomics
                        11.25.6   Edico Genome
                        11.25.7   Genalice
                        11.25.8   Seven Bridges Genomics Inc.
                        11.25.9   Fabric Genomics, Inc. (Formerly Omicia, Inc.)
                        11.25.10  WuxiNextCode
                        11.25.11  Genomatix AG
                        11.25.12  Partek Incorporated
 
12   Research Scope & Methodology
       12.1   Report Scope
       12.2   NGS Informatics and Clinical Genomics Market: Research Methodology
 

List of Tables

Table 2.1    Impact Analysis of the Drivers and Challenges in the Market
Table 2.2    Comparison of Data Storage Requirements
Table 5.1    List of Bodies Providing Guidelines Related to Clinical NGS across the World
Table 5.2    List of Policies and Laws
Table 5.3    List of Most Significant Regulatory Authorities that Regulates Medical Devices
Table 5.4    List of Consortiums and Organizations Operating in the Field of Genomics and NGS Informatics
Table 7.1    Commercially Available Blockchain Assisted Genomic Software Platforms
Table 7.2    Types of Clinical Data Generated from Different Forms of Health IT Systems
Table 7.3    Commercially Available Data Aggregation Software
Table 7.4    AI/Machine Learning and Cloud Computing-based Genomic Platforms
Table 7.5    Commercially Available Precision Medicine Oncology Decision Support Companies
Table 7.6    Aggregate and Synthesize Information
Table 8.1    Commercially Available LIMS Software
Table 8.2    NGS Informatics (Sequencing and Consulting) Service Providers
Table 8.3    Commercially Available Primary and Secondary Analysis Tools Providers
Table 8.4    Different Kinds of Commercial Cloud Providers Along with Their Business Models
Table 8.5    Different Kinds of Academic Cloud Providers Along with Their Business Models
Table 8.6    Commercially Available Primary and Secondary Analysis Tools Providers
Table 10.1    ONC's Precision Medicine Initiative Activities
Table 10.2    NGS informatics and Clinical Genomic Service Providers in Germany
Table 10.3    List of Indian Hospitals or Organizations Providing Precision Medicine Related Services
Table 11.1    Allscripts Healthcare Solutions, Inc.: Recent Developments
Table 11.2    Cota, Inc.: Recent Developments
Table 11.3    CureMatch, Inc.: Recent Developments
Table 11.4    DrChrono Inc.: Recent Developments
Table 11.5    F. Hoffmann-La Roche AG: Recent Developments
Table 11.6    GenomOncology LLC: Recent Developments
Table 11.7    Interpreta, Inc.: Recent Developments
Table 11.8    Illumina, Inc.: Collaborations, Agreements, and Partnerships
Table 11.9    Illumina, Inc.: Acquisition
Table 11.10    IBM Corporation: Recent Developments
Table 11.11    Koninklijke Philips N.V.: Recent Developments
Table 11.12    LunaDNA Inc.: Recent Developments
Table 11.13    Navican Genomics, Inc.: Recent Developments
Table 11.14    N-of-One, Inc.: Recent Developments
Table 11.15    NantHealth, Inc.: Recent Developments
Table 11.16    Orion Health Group Limited: Recent Developments
Table 11.17    QIAGEN N.V.: Acquisition
Table 11.18    QIAGEN N.V.: Collaborations, Partnership, and Agreement
Table 11.19    Sophia Genetics SA: Recent Developments
Table 11.20    Syapse, Inc.: Recent Developments
Table 11.21    SAP SE: Recent Developments
Table 11.22    Tempus Labs, Inc.: Recent Developments
Table 11.23    Verily Life Sciences LLC: Recent Developments

List of Figures
 

Figure 1    The shift from One-Size-Fits-All to targeted Therapy (Precision Medicine)
Figure 2    Percentage of NGS Costs (by Function), 2018 and 2026
Figure 3    Impact Analysis of Market Dynamics
Figure 4    Global NGS Informatics and Clinical Genomics Market, 2018
Figure 5    Share of Key Developments and Strategies
Figure 6    Global NGS Informatics and Clinical Genomics Market (by Product)
Figure 7    Global NGS Informatics and Clinical Genomics Market (by End User)
Figure 8    Global NGS Informatics and Clinical Genomics Market (by Region)
Figure 9    The Future of Global NGS Informatics and Clinical Genomics Market)
Figure 1.1    The Flow of Genomic Data Across the NGS Informatics and Clinical Genomics Value-Chain
Figure 1.2    Different Stages of NGS Data Analysis
Figure 1.3    Approach to Precision Medicine
Figure 1.4    Evolution of Precision Medicine Technology
Figure 1.5    A Plethora of Data Types Catoring to Precision Medicine
Figure 1.6    The Flow of Genomic Data is the Major Barrier in its own inhibition
Figure 2.1    Market Dynamics of Global NGS Informatics and Clinical Genomics Market
Figure 2.2    Plummeting Cost of Genome Sequencing
Figure 2.3    Timeline of the Key Population Genomics Research Projects
Figure 3.1    Key Strategies Employed by Companies in NGS informatics and Clinical Genomics, 2014-2018
Figure 3.2    Key Strategies Employed by Companies in NGS informatics and Clinical Genomics, 2014-2018
Figure 4.1    Porter’s Five Forces Analysis
Figure 4.2    Bargaining Power of Suppliers: Overall Impact
Figure 4.3    Bargaining Power of Buyers: Overall Impact
Figure 4.4    Threat of New Entrant: Overall Impact
Figure 4.5    Threat of Substitute Products: Overall Impact
Figure 4.6    Intensity of Competitive Rivalry: Overall Impact
Figure 8.1    A holistic View of the Diverse Product Segments of Global NGS Informatics Market
Figure 8.2    Global LIMS Market, 2017-2028
Figure 8.3    Standard Workflow of a Laboratory Information System
Figure 8.4    Global NGS Informatics Services Market, 2017-2028
Figure 8.5    First stage of NGS data analysis: Primary analysis: Base calling.
Figure 8.6    Second Stage of NGS Data Analysis: Secondary analysis: Read Alignment and Variant Calling.
Figure 8.7    Global Commercial Primary and Secondary Analysis Tools Market, $Million, 2017-2028
Figure 8.8    Global NGS Data Storage and Computing Market, 2017-2028 ($Million)
Figure 8.9    Global Interpretation and Reporting Tools Market, $Million, 2017-2028
Figure 8.10    Workflow of NGS Tertiary Analysis: Interpretation of NGS Data
Figure 9.1    Global NGS Informatics and Clinical Genomics End User Market (Academic and Research Institutes), $Million, 2017-2028
Figure 9.2    Global NGS Informatics and Clinical Genomics End User Market (Biopharmaceutical Industries), $Million, 2017-2028
Figure 9.3    Global NGS Informatics and Clinical Genomics End User Market (Diagnostic Industry), $Million, 2017-2028
Figure 9.4    Global NGS Informatics and Clinical Genomics End User Market (Government Agencies), $Million, 2017-2028
Figure 9.5    Global NGS Informatics and Clinical Genomics Market (Hospitals and Clinics) $Million, 2017-2028
Figure 10.1    Global NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.2    North America NGS Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 10.3    U.S. NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.4    The U.S. Laboratory Information Management System (LIMS) Market , $Million, 2017-2028
Figure 10.5    The U.S. NGS Informatics Services Market , $Million, 2017-2028
Figure 10.6    The U.S. Commercial Primary and Secondnary Data Analysis Tools Market, $Million, 2017-2028
Figure 10.7    The U.S. Storage and Computing Solutions Market, $Million, 2017-2028
Figure 10.8    The U.S. Interpretation and Reporting Tools Market, $Million, 2017-2028
Figure 10.9    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Academics and Research Institutes), $Million, 2017-2028
Figure 10.10    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Biopharmaceutical Industry), $Million, 2017-2028
Figure 10.11    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Diagnostic Industry), $Million, 2017-2028
Figure 10.12    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Government Agencies), $Million, 2017-2028
Figure 10.13    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Hospitals and Clinics), $Million, 2017-2028
Figure 10.14    Distribution of the Financial Support Provided by the U.S. Government, 2015
Figure 10.15    Canada NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.16    Canada NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.17    Europe NGS Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 10.18    Germany NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.19    Germany NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.20    U.K. NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.21    U.K. NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.22    Italy NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.23    Italy NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.24    France NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.25    France NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.26    Spain NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.27    Spain NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.28    Rest-of-Europe NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.29    Asia-Pacific NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.30    India NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.31    India NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.32    China NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.33    China NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.34    Japan NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.35    Japan NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.36    South Korea NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.37    Australia NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.38    Australia NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.39    Singapore NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.40    Rest-of-Asia-Pacific NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.41    The RoW Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 10.42    Brazil NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.43    Mexico NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.44    Russia NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.45    Israel NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.46    Other countries in “RoW” NGS Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 11.1    Shares of Key Company Profiles
Figure 11.2    Allscripts Healthcare Solutions, Inc.: Product/Service Offerings
Figure 11.3    Allscripts Healthcare Solutions, Inc.: Precision Medicine Solutions
Figure 11.4    Allscripts Healthcare Solutions, Inc.: Overall Financials, 2015-2017
Figure 11.5    Allscripts Healthcare Solutions, Inc.: Net Revenue (by Business Segment), 2015-2017
Figure 11.6    Allscripts Healthcare Solutions, Inc.: Net Revenue (by Region), 2015-2017
Figure 11.7    Allscripts Healthcare Solutions, Inc.: Global Presence
Figure 11.8    Allscripts Healthcare Solutions, Inc.: SWOT Analysis
Figure 11.9    Cota, Inc.: Product Portfolio
Figure 11.10    Cota, Inc.: Global Presence
Figure 11.11    Cota, Inc.: SWOT Analysis
Figure 11.12    CureMatch, Inc.: Product/Service Offerings
Figure 11.13    Merit Medical Systems, Inc: Global Presence
Figure 11.14    CureMatch, Inc.: SWOT Analysis
Figure 11.15    DrChrono Inc.: Overall Product Portfolio
Figure 11.16    DrChrono Inc.: Healthcare IT for Precision Medicine Product Portfolio
Figure 11.17    DrChrono Inc.: Global Presence
Figure 11.18    DrChrono Inc.: SWOT Analysis
Figure 11.19    Epic Systems Corporation: Product/Service Offerings
Figure 11.20    Epic Systems Corporation: Precision Medicine Product Portfolio
Figure 11.21    Epic Systems Corporation: Global Presence
Figure 11.22    Epic Systems Corporation: SWOT Analysis
Figure 11.23    F. Hoffmann-La Roche AG: Overall Product Portfolio
Figure 11.24    F. Hoffmann-La Roche AG: Precision Medicine Product Portfolio
Figure 11.25    F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 11.26    F. Hoffmann-La Roche AG: Net Revenue (by Region), 2015-2017
Figure 11.27    F. Hoffmann-La Roche AG: Net Revenue (by Business Segment),2015-2017
Figure 11.28    F. Hoffmann-La Roche AG: Global Presence
Figure 11.29    F. Hoffmann-La Roche AG: SWOT Analysis
Figure 11.30    GenomOncology, LLC: Product Portfolio
Figure 11.31    GenomOncology, LLC: Global Presence
Figure 11.32    GenomOncology LLC: SWOT Analysis
Figure 11.33    Interpreta, Inc.: Product Portfolio
Figure 11.34    Interpreta, Inc.: Global Presence
Figure 11.35    Interpreta, Inc.: SWOT Analysis
Figure 11.36    Illumina, Inc.: Overall Product Portfolio
Figure 11.37    Illumina, Inc.: Product Portfolio for Global NGS Informatics and Clinical Genomics Market
Figure 11.38    Illumina, Inc.: Overall Financials, 2015-2017
Figure 11.39    Illumina, Inc.: Net Revenue (by Region), 2015-2017
Figure 11.40    Illumina, Inc.: Net Revenue (by Business Segment), 2015-2017
Figure 11.41    Illumina, Inc.: Global Presence
Figure 11.42    Illumina, Inc.: SWOT Analysis
Figure 11.43    IBM Corporation: Product/Service Offerings
Figure 11.44    IBM Corporation: Precision Medicine Product Portfolio
Figure 11.45    IBM Corporation: Overall Financials (2015-2017)
Figure 11.46    IBM Corporation: Net Revenue (by Business Segment), 2015-2017
Figure 11.47    IBM Corporation: Net Revenue (by Region), 2015-17
Figure 11.48    IBM Corporation: Global Presence
Figure 11.49    IBM Corporation: SWOT Analysis
Figure 11.50    Koninklijke Philips N.V.: Product/Service Offerings
Figure 11.51    Koninklijke Philips N.V.: Precision Medicine Product Portfolio
Figure 11.52    Koninklijke Philips N.V.: Overall Financials, 2015-2017
Figure 11.53    Koninklijke Philips N.V.: Net Revenue (by Business Segments), 2015-2017
Figure 11.54    Koninklijke Philips N.V.: Net Revenue (by Region), 2015-2017
Figure 11.55    Koninklijke Philips N.V.: Global Presence
Figure 11.56    Koninklijke Philips N.V.: SWOT Analysis
Figure 11.57    LunaDNA Inc.: Product/Service Offerings
Figure 11.58    LunaDNA Inc.: Global Presence
Figure 11.59    LunaDNA Inc.: SWOT Analysis
Figure 11.60    Navican Genomics, Inc.: Product/Service Offerings
Figure 11.61    Navican Genomics, Inc.: Global Presence
Figure 11.62    Navican Genomics, Inc.: SWOT Analysis
Figure 11.63    N-of-One, Inc.: Product/Service Offerings
Figure 11.64    N-of-One, Inc.: Global Presence
Figure 11.65    N-of-One, Inc.: SWOT Analysis
Figure 11.66    NantHealth, Inc.: Product/Service Offerings
Figure 11.67    NantHealth, Inc.: Precision Medicine Product Portfolio
Figure 11.68    NantHealth, Inc.: Overall Financials
Figure 11.69    NantHealth, Inc.: Net Revenue (by Product Segments), 2015-2017
Figure 11.70    NantHealth, Inc.: Global Presence
Figure 11.71    NantHealth, Inc.: SWOT Analysis
Figure 11.72    Orion Health Group Limited: Product/Service Offerings
Figure 11.73    Orion Health Group Limited: Precision Medicine Product Portfolio
Figure 11.74    Orion Health Group Limited: Overall Financials, 2016-2018
Figure 11.75    Orion Health Group Limited: Net Revenue (by Product/Service Category), 2016-2018
Figure 11.76    Orion Health Group Limited: Net Revenue (by Region), 2016-2018
Figure 11.77    Orion Health Group Limited: Global Presence
Figure 11.78    Orion Health Group Limited: SWOT Analysis
Figure 11.79    QIAGEN N.V.: Overall Product Portfolio
Figure 11.80    QIAGEN N.V.: Product Portfolio for Global NGS Informatics and Clinical Genomics Market
Figure 11.81    QIAGEN N.V.: Overall Financials, 2015-2017
Figure 11.82    QIAGEN N.V.: Net Revenue (by Business Segment), 2015-2017
Figure 11.83    QIAGEN N.V.: Net Revenue (by Region), 2015-2017
Figure 11.84    QIAGEN N.V.: Global Presence
Figure 11.85    QIAGEN N.V.: SWOT Analysis
Figure 11.86    Sophia Genetics SA: Product/Service Offerings
Figure 11.87    Sophia Genetics SA: Global Presence
Figure 11.88    Sophia Genetics SA: SWOT Analysis
Figure 11.89    Syapse, Inc.: Product/Service Offerings
Figure 11.90    Syapse, Inc.: Global Presence
Figure 11.91    Syapse, Inc.: SWOT Analysis
Figure 11.92    SAP SE: Product/Service Offerings
Figure 11.93    SAP SE: Precision Medicine Product Portfolio
Figure 11.94    SAP SE: Overall Financials, 2015-2017
Figure 11.95    SAP SE: Net Revenue (by Business Segments), 2015-2017
Figure 11.96    SAP SE: Net Revenue (by Region), 2015-2017
Figure 11.97    SAP SE: Global Presence
Figure 11.98    SAP SE: SWOT Analysis
Figure 11.99    Tempus Labs, Inc.: Product Portfolio
Figure 11.100    Tempus Labs, Inc.: Global Presence
Figure 11.101    Tempus Labs, Inc.: SWOT Analysis
Figure 11.102    Verily Life Sciences LLC: Projects
Figure 11.103    Verily Life Sciences LLC: Precision Medicine Product Portfolio
Figure 11.104    Verily Life Sciences LLC: Global Presence
Figure 11.105    Verily Life Sciences LLC: SWOT Analysis
Figure 12.1    Scope of the Global NGS Informatics and Clinical Genomics Market
Figure 12.2    Global NGS informatics and Clinical Genomics Market: Research Methodology
Figure 12.3    Primary Research
Figure 12.4    Secondary Research
Figure 12.5    Data Triangulation
Figure 12.6    Top-Down Approach (Segment Wise Analysis)
Figure 17.7    Bottom-Up Approach (Segment Wise Analysis)
Figure 12.8    Assumptions and Limitations
Figure 12.9    Considered Factors for Data Prediction & Modeling

In the last two decades, there have been significant strides made in the field of genomics and the field has so evolved that it is constantly being pushed to work for the facilitation of precision medicine (targeted medicine). The major factors that facilitate large scale research projects aimed at genome sequencing include the falling cost of genome sequencing. Also, the declining cost is catalysing the adoption of genome sequencing in multiple end user segments such as pharmaceutical companies (during clinical trials and drug discovery), hospitals, and speciality clinics. However, as the adoption increases, the amount of data generated from NGS machines also surges exponentially. For successfully understanding hidden patterns underneath this data, there is a strong need for analytical tools which can efficiently interpret, report, and help the stakeholders in the industry to make crucial clinical decisions. In this regard, there is already an abundance of primary and secondary tools, which are about to be commoditized with the standardization of pipelines. However, analysis and interpretation are two significant aspects to this market. While primary and secondary tools (which performs analysis of NGS data) are in abundance, there is a dearth of tertiary analysis tools that caters to the interpretation and reporting of NGS data. Moreover, the price has dropped significantly for sequencing a genome, but the cost of analysing and interpreting NGS data remains on a rise.

Due to the increasing awareness about the medical importance of precision medicine, there has been a flurry of business activities in the NGS informatics and clinical genomics market. Companies are putting significant efforts in the development of the technology for precision medicine applications and have demonstrated an inclination toward partnerships and collaborations, with other firms, mostly software providers with expertise and healthcare institutions.

With 54% share in all the business strategies adopted by companies, partnership and collaborations seem to be the strategy of choice for companies to enter into this market. Companies are focusing on novel software product development and launch to secure early mover’s advantage in the market with this strategy accounting for 18% of the total strategies employed.

Furthermore, the NGS informatics and clinical genomics market is witnessing a steep rise in the launch of new informatics tools. The average frequency of product launched in this market is 10-12 a year. The products available in the global NGS informatics and clinical genomics market encompasses a wide range of software products, platforms and services used for computing, and analysing, interpretation, and storing of NGS data. The market also consists of on-premise as well as cloud-based solutions offering a wide range of primary, secondary, and tertiary (analysis and reporting) of NGS generated data. As of 2018, NGS informatics services is the largest product segment in this market. These services are often provided by NGS instrument providers such as Illumina and ThermoFisher Scientific, among others. With the maturity of the market, the demand for these services will surge due to shift in the end user preference for seamless end-to-end genomic solutions at competitive prices.

The NGS informatics and clinical genomics market has five major end users namely: academic research institutes, biopharmaceutical companies, diagnostic companies, government agencies, and hospitals and clinics. These end users group adopt NGS informatics solutions for a wide range of purposes. As of 2017, the academics and research institutes served as the leading end user segment of the market holding a share of approximately 41% of the overall market. However, biopharmaceutical companies followed by hospitals and clinics are expected to be the leading end-user segments in this market growing with a CAGR of 22.02% and 21.66% respectively, during the forecast period. The reason for this high growth is primarily due to multiple factors such as rising popularity of NGS-based tests among the healthcare organizations, increasing use of NGS tests in drug discovery, and clinical trial, among others.

The global NGS informatics and clinical genomics market encompasses major regions such as North America, Europe, Asia-Pacific, Middle East and Africa, and Rest-of-the-World (RoW). North America is the leading region in the NGS informatics and clinical genomics market accounting for approximately 45.45% and has an estimated value of $380.0 million (as of 2017). The U.S. is the clear regional leader in the North America market with an estimated value of $361.0 million. The major reason for the growth in this region is the rapidly increasing number of genomics projects funded by government which will be providing millions of dollars for the next couple of years to have thousands of patient genomes sequenced.

The dynamics of the overall market depicts that the NGS informatics and clinical genomics space offers huge profitability to investors willing to enter the market. The year 2017 witnessed numerous series of fundings from investors to companies working on data management, analysis, and interpretation of NGS data. For example, companies such as Genoox have been potentially funded ($6 million investment) by Inimiti Capital and Glilot Capital Partners (two Israeli venture capital firms) for developing a platform for interpretation of NGS data through a search engine. A plethora of companies are being invested in for their innovations toward data interpretation and visualization. In the years to come, the scope and scale of sequencing projects will further evolve as the throughput per sample will significantly surge and the cost of sequencing further plummets.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields
 

The global NGS informatics and clinical genomics market is composed of tools, software solutions and services catering for the data analysis needs of the NGS market. Despite the technological advancement in the field of next generation sequencing, analysing huge datasets coming out of sequencers remains a major challenge in the industry that prevents the NGS technology to be used as a routine technique.

There are three significant forms of NGS data analysis: primary, secondary, and tertiary analysis. The software platforms or tools catering for NGS data analysis either perform primary, secondary, and tertiary data analysis. However, there are software packages available which provide end to end (primary to tertiary) data analysis solutions. Some of the major analysis performed by NGS software tools include image acquisition, quality control, base calling, alignment to a reference genome, variant calling, and biological interpretation.

In the primary analysis stage, the raw data is converted to sequence data wherein the base pairs in a genome are typically identified by laser excitation or fluorescence detection. A primary data analysis tool is a part of sequencing instruments and is typically installed on the local hardware systems supporting sequencing instruments. The resultant of this data analysis stage is usually a FASTQ file (string of characters: A, C, T, G, and N). In the secondary data analysis stage, reads generated (short genomic sequences) are aligned against a reference genome. Once the file is aligned, a BAM file is generated which is subject to further refinement steps such as flagging or filtering of duplicate reads, recalibration of quality scores (in the first stage), and variant calling with the help of various statistical modelling techniques. The variant calling step determines the point of difference between the sample and the reference genome. The last and the most complex and time-consuming phase of NGS data analysis is tertiary analysis. This stage aims at identifying which variants in a sample are benign, pathogenic, or VUS (variant of unknown clinical significance). The complexity of the stage can be understood from the fact that one human exome may have approximately 3.2 million variants and interpretation of each of the variants become a daunting task for the industry.

The market report is well-designed to provide an all-inclusive field of vision about the global NGS informatics and clinical genomics market in terms of various factors, such as recent trends, technological advancements, competitive landscape, and regulatory environment of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the global NGS informatics and clinical genomics market. The market has been segmented into “Technology” ‘Products’, ‘End Users’, and ‘Region’. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global NGS informatics and clinical genomics market with the help of the key factors driving the market, challenges, and threats that can possibly inhibit the overall growth of the market and the current investment opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global NGS informatics and clinical genomics market and assesses the factors governing the same.

The answers to the following key questions can be derived from this report:

•    What are the major market drivers, challenges, and opportunities in the global NGS informatics and clinical genomics market?
•    What was the market value of the leading segments and sub-segments of the global NGS informatics and clinical genomics market in 2017?
•    How will each segment of the global NGS informatics and clinical genomics market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
•    What are the influencing factors that may affect the market share of the leading players?
•    How will the industry evolve during the forecast period 2018-2028?
•    What are the key developments and strategies that are implemented by the key players to sustain in this market?
•    What are the potential end users of the global NGS informatics and clinical genomics market? How NGS informatics and clinical genomics software platforms will boost the performance of different end users?
•    Who are the key players in the global NGS informatics and clinical genomics market, and what are their contributions?
•    What is the scope of expansion by the key players of the global NGS informatics and clinical genomics market in Asia-Pacific, Europe, and Middle East?

Furthermore, to bring the competitive landscape of NGS informatics and clinical genomics market into perspective, there is a wide range of providers competing under different sub-segments of the market. For example, there are primary and secondary data analysis tools providers such as Illumina (primary and secondary), ThermoFisher (primary and secondary), Qiagen (primary and secondary), Edico Genome (secondary only), and Genalice among others.  In addition, there is a plethora of companies providing storage and computing solutions (such as Google Cloud, Amazon Web Services and Microsoft, among others), LIMS solutions (such as Thermo Scientific Clinical LIMS, Core LIMS, and STARLIMS, among others) and data interpretation and reporting tools (such as Qiagen (QCI Interpret), Genoox, and Annai Systems, among others)

   Executive Summary
   1   Market Overview
        1.1   Introduction to NGS Informatics and Clinical Genomics
        1.2   Cost of NGS Data Analysis
        1.3   Role of NGS Informatics in Precision Medicine?
        1.4   Approach to Precision Medicine
        1.5   Evolution of Precision Medicine Technology
        1.6   The Wave of Data Types: NGS Data Remains the Leading Data Type for Precision Medicine
                1.6.1   Overview
                1.6.2   Genomic Data
                1.6.3   Lifestyle and Environment
                1.6.4   Health Information
                1.6.5   Social Media
        1.7   Healthcare Information Technology: A Boon for NGS informatics Market
        1.8   The Correlation Between NGS Informatics and Clinical Genomics
        1.9   Technologies with the Potential to Incorporate NGS in a Clinical Setting
                1.9.1   Electronic Health Records (EHR)
                1.9.2   Health Information Exchange
                1.9.3   Clinical Decision Support Systems (CDSS)
                1.9.4   Population Health Management (PHM)
                1.9.5   Blockchain
                1.9.6   Artifical Intelligence/Machine Learning
                1.9.7   Big Data Analytics
 
   2   Market Dynamics
        2.1   Impact Analysis
        2.2   Market Drivers
                2.2.1   Low cost Sequencing Platforms
                2.2.2   Growth in Clinical Application
                2.2.3   Rise in Genomic Data
                2.2.4   Increasing Number of Population Genomics Initiatives
                2.2.5   Advancements in Big Data Technology
                2.2.6   Reducing Cost of Cloud Storage
        2.3   Market Restraints
                2.3.1   Lack of Integration and Interoperability among Existing Information Systems
                2.3.2   Patient Access to Data
                2.3.3   Data Security and Privacy
                2.3.4   Fragmented Research Environment
        2.4   Market Opportunities
                2.4.1   Cross Industry Collaborations between Health Systems, Academia and Health IT Industry
                2.4.2   Investment in Blockchain Technology and Information Security
                2.4.3   Clinical Application Focussed NGS Informatics Products
                2.4.4   Integration of Clinical and Non-Clinical NGS data
                2.4.5   Automation of Sequencing and Interpretation
 
   3   Competitive Insights
        3.1   Key Strategies and Developments
                3.1.1   Partnerships, Joint Ventures, and Collaborations
                3.1.2   Product Development and Launch
                3.1.3   Business Funding and Contracts
                3.1.4   Mergers and Acquisitions
                3.1.5   Approvals and Certifications
                3.1.6   Others
        3.2   Competitive Scenario: Intense Competition within a Converging Market
 
   4   Industry Attractiveness and Insights
        4.1   Porter’s Five Forces Analysis
        4.2   Bargaining Power of Suppliers
        4.3   Bargaining Power of Buyer
        4.4   Threat of New Entrants
                4.4.1   Threat of Substitute Products
                4.4.2   Intensity of Competitive Rivalry
 
   5   Key Industry Insights
        5.1   Introduction
        5.2   Regulatory Bodies
 
   6   Global NGS Informatics and Clinical Genomics Market: Analysis and Forecast
        6.1   Assumptions & Limitations for Market Size Calculations
 
   7   Global NGS Informatics and Clinical Genomics Market (by Technology)
        7.1   Overview
                7.1.1   Blockchain Genomics Platforms
                7.1.2   Data Aggregation Software
                7.1.3   AI/Machine Learning and Cloud Computing based Genomic Platforms
                7.1.4   Clinical Decision Support based Genomic Platforms
                7.1.5   Artificial Intelligence (AI) based Drug Discovery Platforms
 
   8   Global NGS Informatics and Clinical Genomics Market (by Product Type)
        8.1   Laboratory Information Management Systems (LIMS)
        8.2   NGS Informatics Services (Includes both Sequencing and Consulting Services)
        8.3   Commercial Primary and Secondary Data Analysis Tools
                8.3.1   Primary Data Analysis
                8.3.2   Secondary Data Analysis
        8.4   Storage, Infrastructure, and Computing
        8.5   Interpretation (Tertiary Analysis) Tools
 
   9   Global NGS Informatics and Clinical Genomics Market (by End User)
        9.1   Academics and Research Institutes
        9.2   Biopharmaceutical Industry
        9.3   Diagnostic Industry
        9.4   Government Agencies
        9.5   Hospitals and Clinics
 
  10  Global NGS Informatics and Clinical Genomics Market (by Region)
        10.1   Overview
        10.2   North America
                  10.2.1   The U.S.
                  10.2.2   Canada
        10.3   Europe
                  10.3.1   Germany
                  10.3.2   The U.K.
                  10.3.3   Italy
                  10.3.4   France
                  10.3.5   Spain
                  10.3.6   Rest-of-Europe
                               10.3.6.1   Switzerland
        10.4   Asia-Pacific
                  10.4.1   India
                  10.4.2   China
                  10.4.3   Japan
                  10.4.4   South Korea
                  10.4.5   Australia
                  10.4.6   Singapore
                  10.4.7   Rest-of-Asia-Pacific
        10.5   Rest-of-the-World
                  10.5.1   Brazil
                  10.5.2   Mexico
                  10.5.3   Russia
                  10.5.4   Israel
                  10.5.5   Other countries in RoW
                               10.5.5.1   Saudi Arabia
                               10.5.5.2   United Arab Emirates
                               10.5.5.3   South Africa
 
   11   Company Profiles
          11.1   Overview
          11.2   2bPrecise, LLC
                    11.2.1   Company Overview
                    11.2.2   Company Overview
                    11.2.3   Overall Product Portfolio
                    11.2.4   Product Offerings for Precision Medicine
                    11.2.5   Financials
                                 11.2.5.1   Financial Summary
                    11.2.6   Global Presence
                    11.2.7   Recent Developments
                    11.2.8   SWOT Analysis
          11.3   Cota, Inc.
                    11.3.1   Company Overview
                    11.3.2   Product Portfolio
                    11.3.3   Corporate Summary
                    11.3.4   Recent Developments
                    11.3.5   SWOT Analysis
          11.4   CureMatch, Inc.
                    11.4.1   Company Overview
                    11.4.2   Product Portfolio
                    11.4.3   Corporate Summary
                    11.4.4   Global Presence
                    11.4.5   Recent Developments
                    11.4.6   SWOT Analysis
          11.5   DrChrono Inc.
                   11.5.1   Company Overview
                   11.5.2   Overall Product Portfolio
                   11.5.3   Product Portfolio for Healthcare IT Solutions for Precision Medicine
                   11.5.4   Corporate Summary
                   11.5.5   Global Presence
                   11.5.6   Recent Developments
                   11.5.7   SWOT Analysis
         11.6   Epic Systems Corporation
                   11.6.1   Company Overview
                   11.6.2   Overall Product Portfolio
                   11.6.3   Product Offerings for Precision Medicine
                   11.6.4   Corporate Summary
                   11.6.5   SWOT Analysis
         11.7   Flatiron Health, Inc. (Subsidiary of Roche Group Company)
                   11.7.1   Company Overview
         11.8   F. Hoffmann-La Roche AG
                   11.8.1   Company Overview
                   11.8.2   Overall Product Portfolio
                   11.8.3   Product Offering
                   11.8.4   Financials
                                11.8.4.1   Financial Summary
                   11.8.5   Global Presence
                   11.8.6   Recent Developments
                   11.8.7   SWOT Analysis
         11.9   GenomOncology, LLC
                   11.9.1   Company Overview
                   11.9.2   Product Portfolio
                   11.9.3   Corporate Summary
                   11.9.4   Global Presence
                   11.9.5   Recent Developments
                   11.9.6   SWOT Analysis
         11.10  Interpreta, Inc.
                    11.10.1   Company Overview
                    11.10.2   Product Portfolio
                    11.10.3   Corporate Summary
                    11.10.4   Global Presence
                    11.10.5   Recent Developments
                    11.10.6   SWOT Analysis
         11.11  Illumina, Inc.
                   11.11.1   Company Overview
                   11.11.2   Overall Product Portfolio
                   11.11.3   Product Offering
                   11.11.4   Financials
                                 11.11.4.1   Financial Summary
                   11.11.5   Global Presence
                   11.11.6   Recent Developments
                   11.11.7   SWOT Analysis
         11.12  IBM Corporation
                    11.12.1   Company Overview
                    11.12.2   Overall Product Portfolio
                    11.12.3   Precision Medicine Product Portfolio
                    11.12.4   Financials
                                  11.12.4.1   Financial Summary
                    11.12.5   Global Presence
                    11.12.6   Recent Developments
                    11.12.7   SWOT Analysis
         11.13  Koninklijke Philips N.V.
                    11.13.1   Company Overview
                    11.13.2   Overall Product Portfolio
                    11.13.3   Product Offerings for Precision Medicine
                    11.13.4   Financials
                                   11.13.4.1   Financial Summary
                    11.13.5   Global Presence
                    11.13.6   Recent Developments
                    11.13.7   SWOT Analysis
          11.14  LunaDNA Inc.
                    11.14.1   Company Overview
                    11.14.2   Product Portfolio
                    11.14.3   Corporate Summary
                    11.14.4   Global Presence
                    11.14.5   Recent Developments
                    11.14.6   SWOT Analysis
         11.15   Navican Genomics, Inc.
                     11.15.1   Company Overview
                     11.15.2   Product Portfolio
                     11.15.3   Corporate Summary
                     11.15.4   Global Presence
                     11.15.5   Recent Developments
                     11.15.6   SWOT Analysis
          11.16  N-of-One, Inc.
                     11.16.1   Company Overview
                     11.16.2   Product Portfolio
                     11.16.3   Corporate Summary
                     11.16.4   Global Presence
                     11.16.5   Recent Developments
                     11.16.6   SWOT Analysis
          11.17   NantHealth, Inc.
                      11.17.1   Company Overview
                      11.17.2   Overall Product Portfolio
                      11.17.3   Precision Medicine Product Portfolio
                      11.17.4   Financials
                                     11.17.4.1   Financial Summary
                      11.17.5   Global Presence
                      11.17.6   Recent Developments
                      11.17.7   SWOT Analysis
           11.18  Orion Health Group Limited
                      11.18.1   Company Overview
                      11.18.2   Overall Product Portfolio
                      11.18.3   Product Offerings for Precision Medicine
                      11.18.4   Financials
                                     11.18.4.1   Financial Summary
                      11.18.5   Global Presence
                      11.18.6   Recent Developments
                      11.18.7   SWOT Analysis
           11.19  QIAGEN N.V.
                     11.19.1   Company Overview
                     11.19.2   Overall Product Portfolio
                     11.19.3   Product Offering
                     11.19.4   Financials
                                   11.19.4.1   Financial Summary
                     11.19.5   Global Presence
                     11.19.6   Recent Developments
                     11.19.7   SWOT Analysis
          11.20  SOPHiA GENETICS SA
                     11.20.1   Company Overview
                     11.20.2   Product Portfolio
                     11.20.3   Corporate Summary
                     11.20.4   Global Presence
                     11.20.5   Recent Developments
                     11.20.6   SWOT Analysis
          11.21  Syapse, Inc.
                     11.21.1   Company Overview
                     11.21.2   Product Portfolio
                     11.21.3   Corporate Summary
                     11.21.4   Global Presence
                     11.21.5   Recent Developments
                     11.21.6   SWOT Analysis
          11.22  SAP SE
                     11.22.1   Company Overview
                     11.22.2   Overall Product Portfolio
                     11.22.3   Product Offerings for Precision Medicine
                     11.22.4   Financials
                                    11.22.4.1   Financial Summary
                     11.22.5   Global Presence
                     11.22.6   Recent Developments
                     11.22.7   SWOT Analysis
           11.23  Tempus Labs, Inc.
                      11.23.1   Company Overview
                      11.23.2   Product Portfolio
                      11.23.3   Corporate Summary
                      11.23.4   Global Presence
                      11.23.5   Recent Developments
                      11.23.6   SWOT Analysis
            11.24  Verily Life Sciences LLC
                       11.24.1   Company Overview
                       11.24.2   Overall Product Portfolio
                       11.24.3   Product Offerings for Precision Medicine
                       11.24.4   Corporate Summary
                       11.24.5   Global Presence
                       11.24.6   Recent Developments
                       11.24.7   SWOT Analysis
             11.25  Snapshot of Other Key Industry Players
                        11.25.1   Beijing Genomic Institute (BGI)
                        11.25.2   Amazon Web Services, Inc.
                        11.25.3   DNAnexus, Inc.
                        11.25.4   DNASTAR
                        11.25.5   Eagle Genomics
                        11.25.6   Edico Genome
                        11.25.7   Genalice
                        11.25.8   Seven Bridges Genomics Inc.
                        11.25.9   Fabric Genomics, Inc. (Formerly Omicia, Inc.)
                        11.25.10  WuxiNextCode
                        11.25.11  Genomatix AG
                        11.25.12  Partek Incorporated
 
12   Research Scope & Methodology
       12.1   Report Scope
       12.2   NGS Informatics and Clinical Genomics Market: Research Methodology
 

List of Tables

Table 2.1    Impact Analysis of the Drivers and Challenges in the Market
Table 2.2    Comparison of Data Storage Requirements
Table 5.1    List of Bodies Providing Guidelines Related to Clinical NGS across the World
Table 5.2    List of Policies and Laws
Table 5.3    List of Most Significant Regulatory Authorities that Regulates Medical Devices
Table 5.4    List of Consortiums and Organizations Operating in the Field of Genomics and NGS Informatics
Table 7.1    Commercially Available Blockchain Assisted Genomic Software Platforms
Table 7.2    Types of Clinical Data Generated from Different Forms of Health IT Systems
Table 7.3    Commercially Available Data Aggregation Software
Table 7.4    AI/Machine Learning and Cloud Computing-based Genomic Platforms
Table 7.5    Commercially Available Precision Medicine Oncology Decision Support Companies
Table 7.6    Aggregate and Synthesize Information
Table 8.1    Commercially Available LIMS Software
Table 8.2    NGS Informatics (Sequencing and Consulting) Service Providers
Table 8.3    Commercially Available Primary and Secondary Analysis Tools Providers
Table 8.4    Different Kinds of Commercial Cloud Providers Along with Their Business Models
Table 8.5    Different Kinds of Academic Cloud Providers Along with Their Business Models
Table 8.6    Commercially Available Primary and Secondary Analysis Tools Providers
Table 10.1    ONC's Precision Medicine Initiative Activities
Table 10.2    NGS informatics and Clinical Genomic Service Providers in Germany
Table 10.3    List of Indian Hospitals or Organizations Providing Precision Medicine Related Services
Table 11.1    Allscripts Healthcare Solutions, Inc.: Recent Developments
Table 11.2    Cota, Inc.: Recent Developments
Table 11.3    CureMatch, Inc.: Recent Developments
Table 11.4    DrChrono Inc.: Recent Developments
Table 11.5    F. Hoffmann-La Roche AG: Recent Developments
Table 11.6    GenomOncology LLC: Recent Developments
Table 11.7    Interpreta, Inc.: Recent Developments
Table 11.8    Illumina, Inc.: Collaborations, Agreements, and Partnerships
Table 11.9    Illumina, Inc.: Acquisition
Table 11.10    IBM Corporation: Recent Developments
Table 11.11    Koninklijke Philips N.V.: Recent Developments
Table 11.12    LunaDNA Inc.: Recent Developments
Table 11.13    Navican Genomics, Inc.: Recent Developments
Table 11.14    N-of-One, Inc.: Recent Developments
Table 11.15    NantHealth, Inc.: Recent Developments
Table 11.16    Orion Health Group Limited: Recent Developments
Table 11.17    QIAGEN N.V.: Acquisition
Table 11.18    QIAGEN N.V.: Collaborations, Partnership, and Agreement
Table 11.19    Sophia Genetics SA: Recent Developments
Table 11.20    Syapse, Inc.: Recent Developments
Table 11.21    SAP SE: Recent Developments
Table 11.22    Tempus Labs, Inc.: Recent Developments
Table 11.23    Verily Life Sciences LLC: Recent Developments

List of Figures
 

Figure 1    The shift from One-Size-Fits-All to targeted Therapy (Precision Medicine)
Figure 2    Percentage of NGS Costs (by Function), 2018 and 2026
Figure 3    Impact Analysis of Market Dynamics
Figure 4    Global NGS Informatics and Clinical Genomics Market, 2018
Figure 5    Share of Key Developments and Strategies
Figure 6    Global NGS Informatics and Clinical Genomics Market (by Product)
Figure 7    Global NGS Informatics and Clinical Genomics Market (by End User)
Figure 8    Global NGS Informatics and Clinical Genomics Market (by Region)
Figure 9    The Future of Global NGS Informatics and Clinical Genomics Market)
Figure 1.1    The Flow of Genomic Data Across the NGS Informatics and Clinical Genomics Value-Chain
Figure 1.2    Different Stages of NGS Data Analysis
Figure 1.3    Approach to Precision Medicine
Figure 1.4    Evolution of Precision Medicine Technology
Figure 1.5    A Plethora of Data Types Catoring to Precision Medicine
Figure 1.6    The Flow of Genomic Data is the Major Barrier in its own inhibition
Figure 2.1    Market Dynamics of Global NGS Informatics and Clinical Genomics Market
Figure 2.2    Plummeting Cost of Genome Sequencing
Figure 2.3    Timeline of the Key Population Genomics Research Projects
Figure 3.1    Key Strategies Employed by Companies in NGS informatics and Clinical Genomics, 2014-2018
Figure 3.2    Key Strategies Employed by Companies in NGS informatics and Clinical Genomics, 2014-2018
Figure 4.1    Porter’s Five Forces Analysis
Figure 4.2    Bargaining Power of Suppliers: Overall Impact
Figure 4.3    Bargaining Power of Buyers: Overall Impact
Figure 4.4    Threat of New Entrant: Overall Impact
Figure 4.5    Threat of Substitute Products: Overall Impact
Figure 4.6    Intensity of Competitive Rivalry: Overall Impact
Figure 8.1    A holistic View of the Diverse Product Segments of Global NGS Informatics Market
Figure 8.2    Global LIMS Market, 2017-2028
Figure 8.3    Standard Workflow of a Laboratory Information System
Figure 8.4    Global NGS Informatics Services Market, 2017-2028
Figure 8.5    First stage of NGS data analysis: Primary analysis: Base calling.
Figure 8.6    Second Stage of NGS Data Analysis: Secondary analysis: Read Alignment and Variant Calling.
Figure 8.7    Global Commercial Primary and Secondary Analysis Tools Market, $Million, 2017-2028
Figure 8.8    Global NGS Data Storage and Computing Market, 2017-2028 ($Million)
Figure 8.9    Global Interpretation and Reporting Tools Market, $Million, 2017-2028
Figure 8.10    Workflow of NGS Tertiary Analysis: Interpretation of NGS Data
Figure 9.1    Global NGS Informatics and Clinical Genomics End User Market (Academic and Research Institutes), $Million, 2017-2028
Figure 9.2    Global NGS Informatics and Clinical Genomics End User Market (Biopharmaceutical Industries), $Million, 2017-2028
Figure 9.3    Global NGS Informatics and Clinical Genomics End User Market (Diagnostic Industry), $Million, 2017-2028
Figure 9.4    Global NGS Informatics and Clinical Genomics End User Market (Government Agencies), $Million, 2017-2028
Figure 9.5    Global NGS Informatics and Clinical Genomics Market (Hospitals and Clinics) $Million, 2017-2028
Figure 10.1    Global NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.2    North America NGS Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 10.3    U.S. NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.4    The U.S. Laboratory Information Management System (LIMS) Market , $Million, 2017-2028
Figure 10.5    The U.S. NGS Informatics Services Market , $Million, 2017-2028
Figure 10.6    The U.S. Commercial Primary and Secondnary Data Analysis Tools Market, $Million, 2017-2028
Figure 10.7    The U.S. Storage and Computing Solutions Market, $Million, 2017-2028
Figure 10.8    The U.S. Interpretation and Reporting Tools Market, $Million, 2017-2028
Figure 10.9    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Academics and Research Institutes), $Million, 2017-2028
Figure 10.10    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Biopharmaceutical Industry), $Million, 2017-2028
Figure 10.11    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Diagnostic Industry), $Million, 2017-2028
Figure 10.12    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Government Agencies), $Million, 2017-2028
Figure 10.13    The U.S. NGS Informatics and Clinical Genomics End Users Market (By Hospitals and Clinics), $Million, 2017-2028
Figure 10.14    Distribution of the Financial Support Provided by the U.S. Government, 2015
Figure 10.15    Canada NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.16    Canada NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.17    Europe NGS Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 10.18    Germany NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.19    Germany NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.20    U.K. NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.21    U.K. NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.22    Italy NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.23    Italy NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.24    France NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.25    France NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.26    Spain NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.27    Spain NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.28    Rest-of-Europe NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.29    Asia-Pacific NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.30    India NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.31    India NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.32    China NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.33    China NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.34    Japan NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.35    Japan NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.36    South Korea NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.37    Australia NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.38    Australia NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.39    Singapore NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.40    Rest-of-Asia-Pacific NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.41    The RoW Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 10.42    Brazil NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.43    Mexico NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.44    Russia NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.45    Israel NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.46    Other countries in “RoW” NGS Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 11.1    Shares of Key Company Profiles
Figure 11.2    Allscripts Healthcare Solutions, Inc.: Product/Service Offerings
Figure 11.3    Allscripts Healthcare Solutions, Inc.: Precision Medicine Solutions
Figure 11.4    Allscripts Healthcare Solutions, Inc.: Overall Financials, 2015-2017
Figure 11.5    Allscripts Healthcare Solutions, Inc.: Net Revenue (by Business Segment), 2015-2017
Figure 11.6    Allscripts Healthcare Solutions, Inc.: Net Revenue (by Region), 2015-2017
Figure 11.7    Allscripts Healthcare Solutions, Inc.: Global Presence
Figure 11.8    Allscripts Healthcare Solutions, Inc.: SWOT Analysis
Figure 11.9    Cota, Inc.: Product Portfolio
Figure 11.10    Cota, Inc.: Global Presence
Figure 11.11    Cota, Inc.: SWOT Analysis
Figure 11.12    CureMatch, Inc.: Product/Service Offerings
Figure 11.13    Merit Medical Systems, Inc: Global Presence
Figure 11.14    CureMatch, Inc.: SWOT Analysis
Figure 11.15    DrChrono Inc.: Overall Product Portfolio
Figure 11.16    DrChrono Inc.: Healthcare IT for Precision Medicine Product Portfolio
Figure 11.17    DrChrono Inc.: Global Presence
Figure 11.18    DrChrono Inc.: SWOT Analysis
Figure 11.19    Epic Systems Corporation: Product/Service Offerings
Figure 11.20    Epic Systems Corporation: Precision Medicine Product Portfolio
Figure 11.21    Epic Systems Corporation: Global Presence
Figure 11.22    Epic Systems Corporation: SWOT Analysis
Figure 11.23    F. Hoffmann-La Roche AG: Overall Product Portfolio
Figure 11.24    F. Hoffmann-La Roche AG: Precision Medicine Product Portfolio
Figure 11.25    F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 11.26    F. Hoffmann-La Roche AG: Net Revenue (by Region), 2015-2017
Figure 11.27    F. Hoffmann-La Roche AG: Net Revenue (by Business Segment),2015-2017
Figure 11.28    F. Hoffmann-La Roche AG: Global Presence
Figure 11.29    F. Hoffmann-La Roche AG: SWOT Analysis
Figure 11.30    GenomOncology, LLC: Product Portfolio
Figure 11.31    GenomOncology, LLC: Global Presence
Figure 11.32    GenomOncology LLC: SWOT Analysis
Figure 11.33    Interpreta, Inc.: Product Portfolio
Figure 11.34    Interpreta, Inc.: Global Presence
Figure 11.35    Interpreta, Inc.: SWOT Analysis
Figure 11.36    Illumina, Inc.: Overall Product Portfolio
Figure 11.37    Illumina, Inc.: Product Portfolio for Global NGS Informatics and Clinical Genomics Market
Figure 11.38    Illumina, Inc.: Overall Financials, 2015-2017
Figure 11.39    Illumina, Inc.: Net Revenue (by Region), 2015-2017
Figure 11.40    Illumina, Inc.: Net Revenue (by Business Segment), 2015-2017
Figure 11.41    Illumina, Inc.: Global Presence
Figure 11.42    Illumina, Inc.: SWOT Analysis
Figure 11.43    IBM Corporation: Product/Service Offerings
Figure 11.44    IBM Corporation: Precision Medicine Product Portfolio
Figure 11.45    IBM Corporation: Overall Financials (2015-2017)
Figure 11.46    IBM Corporation: Net Revenue (by Business Segment), 2015-2017
Figure 11.47    IBM Corporation: Net Revenue (by Region), 2015-17
Figure 11.48    IBM Corporation: Global Presence
Figure 11.49    IBM Corporation: SWOT Analysis
Figure 11.50    Koninklijke Philips N.V.: Product/Service Offerings
Figure 11.51    Koninklijke Philips N.V.: Precision Medicine Product Portfolio
Figure 11.52    Koninklijke Philips N.V.: Overall Financials, 2015-2017
Figure 11.53    Koninklijke Philips N.V.: Net Revenue (by Business Segments), 2015-2017
Figure 11.54    Koninklijke Philips N.V.: Net Revenue (by Region), 2015-2017
Figure 11.55    Koninklijke Philips N.V.: Global Presence
Figure 11.56    Koninklijke Philips N.V.: SWOT Analysis
Figure 11.57    LunaDNA Inc.: Product/Service Offerings
Figure 11.58    LunaDNA Inc.: Global Presence
Figure 11.59    LunaDNA Inc.: SWOT Analysis
Figure 11.60    Navican Genomics, Inc.: Product/Service Offerings
Figure 11.61    Navican Genomics, Inc.: Global Presence
Figure 11.62    Navican Genomics, Inc.: SWOT Analysis
Figure 11.63    N-of-One, Inc.: Product/Service Offerings
Figure 11.64    N-of-One, Inc.: Global Presence
Figure 11.65    N-of-One, Inc.: SWOT Analysis
Figure 11.66    NantHealth, Inc.: Product/Service Offerings
Figure 11.67    NantHealth, Inc.: Precision Medicine Product Portfolio
Figure 11.68    NantHealth, Inc.: Overall Financials
Figure 11.69    NantHealth, Inc.: Net Revenue (by Product Segments), 2015-2017
Figure 11.70    NantHealth, Inc.: Global Presence
Figure 11.71    NantHealth, Inc.: SWOT Analysis
Figure 11.72    Orion Health Group Limited: Product/Service Offerings
Figure 11.73    Orion Health Group Limited: Precision Medicine Product Portfolio
Figure 11.74    Orion Health Group Limited: Overall Financials, 2016-2018
Figure 11.75    Orion Health Group Limited: Net Revenue (by Product/Service Category), 2016-2018
Figure 11.76    Orion Health Group Limited: Net Revenue (by Region), 2016-2018
Figure 11.77    Orion Health Group Limited: Global Presence
Figure 11.78    Orion Health Group Limited: SWOT Analysis
Figure 11.79    QIAGEN N.V.: Overall Product Portfolio
Figure 11.80    QIAGEN N.V.: Product Portfolio for Global NGS Informatics and Clinical Genomics Market
Figure 11.81    QIAGEN N.V.: Overall Financials, 2015-2017
Figure 11.82    QIAGEN N.V.: Net Revenue (by Business Segment), 2015-2017
Figure 11.83    QIAGEN N.V.: Net Revenue (by Region), 2015-2017
Figure 11.84    QIAGEN N.V.: Global Presence
Figure 11.85    QIAGEN N.V.: SWOT Analysis
Figure 11.86    Sophia Genetics SA: Product/Service Offerings
Figure 11.87    Sophia Genetics SA: Global Presence
Figure 11.88    Sophia Genetics SA: SWOT Analysis
Figure 11.89    Syapse, Inc.: Product/Service Offerings
Figure 11.90    Syapse, Inc.: Global Presence
Figure 11.91    Syapse, Inc.: SWOT Analysis
Figure 11.92    SAP SE: Product/Service Offerings
Figure 11.93    SAP SE: Precision Medicine Product Portfolio
Figure 11.94    SAP SE: Overall Financials, 2015-2017
Figure 11.95    SAP SE: Net Revenue (by Business Segments), 2015-2017
Figure 11.96    SAP SE: Net Revenue (by Region), 2015-2017
Figure 11.97    SAP SE: Global Presence
Figure 11.98    SAP SE: SWOT Analysis
Figure 11.99    Tempus Labs, Inc.: Product Portfolio
Figure 11.100    Tempus Labs, Inc.: Global Presence
Figure 11.101    Tempus Labs, Inc.: SWOT Analysis
Figure 11.102    Verily Life Sciences LLC: Projects
Figure 11.103    Verily Life Sciences LLC: Precision Medicine Product Portfolio
Figure 11.104    Verily Life Sciences LLC: Global Presence
Figure 11.105    Verily Life Sciences LLC: SWOT Analysis
Figure 12.1    Scope of the Global NGS Informatics and Clinical Genomics Market
Figure 12.2    Global NGS informatics and Clinical Genomics Market: Research Methodology
Figure 12.3    Primary Research
Figure 12.4    Secondary Research
Figure 12.5    Data Triangulation
Figure 12.6    Top-Down Approach (Segment Wise Analysis)
Figure 17.7    Bottom-Up Approach (Segment Wise Analysis)
Figure 12.8    Assumptions and Limitations
Figure 12.9    Considered Factors for Data Prediction & Modeling

In the last two decades, there have been significant strides made in the field of genomics and the field has so evolved that it is constantly being pushed to work for the facilitation of precision medicine (targeted medicine). The major factors that facilitate large scale research projects aimed at genome sequencing include the falling cost of genome sequencing. Also, the declining cost is catalysing the adoption of genome sequencing in multiple end user segments such as pharmaceutical companies (during clinical trials and drug discovery), hospitals, and speciality clinics. However, as the adoption increases, the amount of data generated from NGS machines also surges exponentially. For successfully understanding hidden patterns underneath this data, there is a strong need for analytical tools which can efficiently interpret, report, and help the stakeholders in the industry to make crucial clinical decisions. In this regard, there is already an abundance of primary and secondary tools, which are about to be commoditized with the standardization of pipelines. However, analysis and interpretation are two significant aspects to this market. While primary and secondary tools (which performs analysis of NGS data) are in abundance, there is a dearth of tertiary analysis tools that caters to the interpretation and reporting of NGS data. Moreover, the price has dropped significantly for sequencing a genome, but the cost of analysing and interpreting NGS data remains on a rise.

Due to the increasing awareness about the medical importance of precision medicine, there has been a flurry of business activities in the NGS informatics and clinical genomics market. Companies are putting significant efforts in the development of the technology for precision medicine applications and have demonstrated an inclination toward partnerships and collaborations, with other firms, mostly software providers with expertise and healthcare institutions.

With 54% share in all the business strategies adopted by companies, partnership and collaborations seem to be the strategy of choice for companies to enter into this market. Companies are focusing on novel software product development and launch to secure early mover’s advantage in the market with this strategy accounting for 18% of the total strategies employed.

Furthermore, the NGS informatics and clinical genomics market is witnessing a steep rise in the launch of new informatics tools. The average frequency of product launched in this market is 10-12 a year. The products available in the global NGS informatics and clinical genomics market encompasses a wide range of software products, platforms and services used for computing, and analysing, interpretation, and storing of NGS data. The market also consists of on-premise as well as cloud-based solutions offering a wide range of primary, secondary, and tertiary (analysis and reporting) of NGS generated data. As of 2018, NGS informatics services is the largest product segment in this market. These services are often provided by NGS instrument providers such as Illumina and ThermoFisher Scientific, among others. With the maturity of the market, the demand for these services will surge due to shift in the end user preference for seamless end-to-end genomic solutions at competitive prices.

The NGS informatics and clinical genomics market has five major end users namely: academic research institutes, biopharmaceutical companies, diagnostic companies, government agencies, and hospitals and clinics. These end users group adopt NGS informatics solutions for a wide range of purposes. As of 2017, the academics and research institutes served as the leading end user segment of the market holding a share of approximately 41% of the overall market. However, biopharmaceutical companies followed by hospitals and clinics are expected to be the leading end-user segments in this market growing with a CAGR of 22.02% and 21.66% respectively, during the forecast period. The reason for this high growth is primarily due to multiple factors such as rising popularity of NGS-based tests among the healthcare organizations, increasing use of NGS tests in drug discovery, and clinical trial, among others.

The global NGS informatics and clinical genomics market encompasses major regions such as North America, Europe, Asia-Pacific, Middle East and Africa, and Rest-of-the-World (RoW). North America is the leading region in the NGS informatics and clinical genomics market accounting for approximately 45.45% and has an estimated value of $380.0 million (as of 2017). The U.S. is the clear regional leader in the North America market with an estimated value of $361.0 million. The major reason for the growth in this region is the rapidly increasing number of genomics projects funded by government which will be providing millions of dollars for the next couple of years to have thousands of patient genomes sequenced.

The dynamics of the overall market depicts that the NGS informatics and clinical genomics space offers huge profitability to investors willing to enter the market. The year 2017 witnessed numerous series of fundings from investors to companies working on data management, analysis, and interpretation of NGS data. For example, companies such as Genoox have been potentially funded ($6 million investment) by Inimiti Capital and Glilot Capital Partners (two Israeli venture capital firms) for developing a platform for interpretation of NGS data through a search engine. A plethora of companies are being invested in for their innovations toward data interpretation and visualization. In the years to come, the scope and scale of sequencing projects will further evolve as the throughput per sample will significantly surge and the cost of sequencing further plummets.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields


related reports





Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors